Business
Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update
- Continued execution of multiple ongoing clinical studies for the treatment of highly resistant tumors and viruses - - Key clinical and regulatory milestones
About this update from Moleculin Biotech, Inc.
[{"type":"text","content":"- Continued execution of multiple ongoing clinical studies for the treatment of highly resistant tumors and viruses -\n - Key clinical and regulatory milestones throughout next 18 months including topline results from the ongoing Phase 1/2 study of Annamycin for treatment of AML and interim data from U.S. Phase 1b/2 study of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases -\n\n\nHOUSTON, Aug. 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the quarter ended June 30, 2021. The Company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.\n\n \n \n \n \n \n \n\n \n\"I am pleased with the progress made over the course of the past quarter, of particular note, in the clinical development program for Annamycin, our next-generation anthracycline. We are committed to advancing our three core technologies to meet the needs in a number of oncology and viral indications. We believe the next 18 months hold a number of key inflection points and value drivers for the Company. We believe Moleculin is well-positioned to continue building momentum and drive shareholder value in the near- and long-term,\" commented Walter Klemp, Chairman and CEO of Moleculin.\nRecent Highlights \nReceived approval to extend dose escalation in Phase 1/2 European clinical trial evaluating Annamycin for the treatment of acute myeloid leukemia (AML). Commenced enrollment and dosed the first subject in its U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases. Held further meetings with the MHRA in the UK regarding a healthy volunteer trial with WP1122 for the treatment of COVID-19. Programs Update \nNext Generation Anthracycline - Annamycin\nAnnamycin, the Company's next-generation anthracycline was designed to be noncardiotoxic (unlike all currently approved anthracyclines) and has demonstrated its lack of cardiotoxicity in recently conducted human clinical trials for the treatment of AML. The Company believes that, because of this unique improvement in safety, the use of Annamycin may not face the...